Results 71 to 80 of about 2,198,265 (159)

Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis

Pacing and Clinical Electrophysiology, Volume 49, Issue 7, Page 954-961, July 2026.
ABSTRACT Introduction Cardiac amyloidosis can cause congestive heart failure, arrhythmias, and heart blocks, which frequently require cardiac device implantation (CDI). However, the differences between light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis CDI requirements are unknown. Methods A retrospective analysis was conducted using the
Bilal Hussain, Sanchit Duhan, Khawaja Hassan Akhtar, Amith Reddy Seri, Krittapoom Akrawinthawong, Janardhana Gorthi, Bijeta Keisham, Tarun Dasari   +7 more
wiley   +1 more source

Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice

Cardiology and Therapy
Introduction Acoramidis, an oral transthyretin stabilizer that achieves near-complete stabilization, is approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on the phase 3 study, ATTRibute-CM (NCT03860935).
Marianna Fontana, Francesco Cappelli, Julian D. Gillmore, Laura Obici, Fabian aus dem Siepen, Philippe Debonnaire, Esther Gonzalez-Lopez, Marcel Schulze, Kai Vogtländer, Antonio Ciaccia, Martin Merz, Pablo Garcia-Pavia   +11 more
doaj   +1 more source

Prevalence and incidence of amyloid transthyretin amyloidosis in the USA: insights from claims databases and electronic health records

Open Heart
Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with cardiomyopathy (ATTR-CM), polyneuropathy (ATTR-PN) or both (ATTR-mixed).
Xiaolei Li, Pedro A Laires, Aishwarya M Uday, Candida Cristina Quarta, Ana Martins Silva   +4 more
doaj   +1 more source

Characterizing the Fate of Anti‐CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
ABSTRACT Extracellular vesicles (EVs) are promising delivery vehicles capable of transporting therapeutic agents across biological barriers. However, native EVs primarily accumulate in liver, spleen and lungs, limiting targeted delivery to disease sites.
Michiel De Coster, Lukas Hyka, Sophie De Cock, Sofie Meeussen, Zuowei Wang, Chenggong Tu, Sophie Hernot, Nick Devoogdt, Guido David, Kim De Veirman, Karin Vanderkerken, Eline Menu, Pascale Zimmermann, Elke De Bruyne   +13 more
wiley   +1 more source

Health Care Resource Utilization in Transthyretin Amyloid Cardiomyopathy Compared With Non‐amyloid Heart Failure and the General Population

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive, fatal disease associated with a substantial health care system burden.
Justin L. Grodin, Ahmad Masri, Richard Wright, Jean‐François Tamby, Heather Falvey, Liana Hennum, Margarita Udall, Chaitanya Badwe, Melissa Allison, Rakesh Ramesh, Shradha Sanghi, Sandesh Dev, Jose Nativi‐Nicolau   +12 more
doaj   +1 more source

Distribution of ATTR-CM cases, from 2014 to 2021, according to the state of residence.

Distribution of ATTR-CM cases, from 2014 to 2021, according to the state of residence.
Fabio Fernandes (3386423), Isabella Zuppo Laper (17972784), Marcus Vinicius Simões (5224412), Claudenice Leite Bertoli de Souza (17972790), Ariane de Jesus Lopes de Abreu (14425084), Rafaela Vansan Ferreira (14425090), Edileide de Barros Correia (17972793), Guilherme Silva Julian (8520117), Cecilia Camacho-Hubner (17972787)   +8 more
core   +1 more source

Incidence and Predictors of Right Ventricular Reverse Remodeling in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis

Biomedicines
Background/Objectives: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), the effect of tafamidis on right ventricular (RV) dysfunction has been poorly investigated.
Nicoleta Nita, Dominik Felbel, Michael Paukovitsch, Felix von Sanden, Elene Walter, Rima Melnic, Wolfgang Rottbauer, Dominik Buckert, Johannes Mörike   +8 more
doaj   +1 more source

Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) [PDF]

, 2017
Transthyretin amyloidosis is a rare, life-threatening disease resulting from aggregation and deposition of transthyretin amyloid fibrils in various tissues.
Perry Elliott, Merlini, G, Flynn, A., Hahn, C, Balarama Gundapaneni, Carolyn Hahn, Riley, Steven, Rapezzi, Claudio, Alison Flynn, Jeffrey Schwartz, Marla B. Sultan, ATTR-ACT Study Investigators, Hahn, C., Investigators, Attr-Act Study, Hahn, Carolyn, Merlini, Giampaolo, Sultan, M. B., Rapezzi, C., Schwartz, J, Flynn, Alison, Sultan, Marla B., Elliott, P, Claudio Rapezzi, Schwartz, J., Mathew S. Maurer, Sultan, MB, Sanjiv J. Shah, Merlini, G., Gundapaneni, Balarama, Shah, S. J., Shah, Sanjiv J., Gundapaneni, B, Maurer, Mathew S., Márcia Waddington Cruz, Riley, S., Cruz, Márcia Waddington, Gundapaneni, B., Elliott, P., Giampaolo Merlini, Cruz, M. W., Rapezzi, C, Maurer, M. S., Maurer, MS, Elliott, Perry, Flynn, A, Cruz, MW, Steven Riley, Riley, S, Schwartz, Jeffrey, Shah, SJ   +49 more
core   +1 more source

Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction

Annals of Medicine
Introduction Current guidelines recommend suspecting transthyretin amyloid cardiomyopathy (ATTR-CM) in patients over 65 years of age with unexplained left ventricular (LV) hypertrophy in a non-dilated LV, heart failure (HF) and preserved ejection ...
Anouk Achten, Steven A. Muller, Sandra Sanders-van Wijk, Manon G. van der Meer, Pim van der Harst, Peter van Tintelen, Anneline SJM te Riele, Vanessa van Empel, Marish IFJ Oerlemans, Christian Knackstedt   +9 more
doaj   +1 more source

Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial

, 2020
Transthyretin cardiomyopathy (ATTR-CM) is an underdiagnosed, fatal disease caused by the deposition of transthyretin amyloid fibrils in the heart leading to heart failure (HF).
Shah, Sanjiv, Merlini, Giampaolo, Rapezzi, Claudio, Drachman, Brian, Elliott, Perry, Velazquez, Eric, Gundapaneni, Balarama, Damy, Thibaud, Lenihan, Daniel, Sultan, Marla, Berk, John, Schwartz, Jeffrey, Witteles, Ronald, Cruz, Márcia Waddington, Gottlieb, Stephen, Judge, Daniel, Hanna, Mazen, Hoffman, James, Patterson, Terrell, Grogan, Martha, Hummel, Scott   +20 more
core   +1 more source